@phdthesis{Heinz2023,
  author    = {Heinz, Christine Silvia},
  title     = {Synthesis of Analogues and Hybrid Ligands of Pilocarpine for the Study of Muscarinic Receptor Dynamics},
  doi       = {10.25972/OPUS-28148},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-281486},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Muscarinic acetylcholine receptors (mAChRs) are involved in signal transmission at the synapses of the parasympathetic nervous system. The five subtypes of mAChRs regulate various body functions such as heart function, gland secretion, memory, and learning. For the development of drugs with the least side-effects possible, the molecular causes of subtype selectivity and signalling bias are under investigation. In this context, the study of dualsteric ligands binding simultaneously to the orthosteric and the allosteric binding sites of the receptor is of high interest. To date, dualsteric ligands were synthesised as hybrids of full agonists or superagonists being the orthosteric element, linked to known subtype selective allosteric fragments. In this work, the existing library was expanded to hybrid ligands based on the partial agonist pilocarpine. A suitable linker attachment point to pilocarpine was investigated. For this aim, pilocarpine (2), isopilocarpine (15), pilosinine (16) and desmethyl pilosinine (35) were synthesised as orthosteric ligands and orthosteric fragments for the construction of the hybrid molecules (Figure 42). Pilocarpine was liberated from the commercial hydrochloride or nitrate salt and isopilocarpine was generated by epimerisation of pilocarpine. Pilosinine was synthesised in a Michael addition reaction of a dithiane carrying the imidazole moiety 82 onto the lactone precursor furan-2(5H)-one (83) followed by complete deprotection (Figure 43a).[133] The desmethyl pilosinine (35) was obtained in a newly developed synthetic route based on a Horner-Wadsworth-Emmons (HWE) reaction to build the methylene bridge between the imidazole aldehyde and the precursor of the lactone moiety 57 (Figure 43b). All four orthosters were converted to the respective dualsteric compounds with a naphmethonium fragment as allosteric moiety. The four orthosteric fragments and the four hybrid molecules with a linker length of six methylene units were tested for their dose dependent G protein recruitment at the receptor subtypes M1-5 using a mini-G nanoBRET assay. The study of the orthosteric ligands revealed that pilocarpine has the highest ability of all four orthosters to induce activity at all receptor subtypes. A change of the cis- to a trans-configuration of the lactone substituents or a complete removal of the ethyl substituent provoked a significant reduction of activity. Removal of the methyl substituent of the imidazole moiety led to improved receptor activation. The efficacies of the hybrid ligands show that the linker attachment at the imidazole moiety of pilocarpine and its analogues does not abolish activity and hybrid formation of isopilocarpine even improved receptor activation. Thus, the linker attachment point seems a valid choice, but linker length might not be optimum. In contrast to the orthosters, the trans-substitution of the lactone was advantageous for receptor activation of the hybrid ligands. The hybrid without a methyl substituent at the imidazole (69) had an increased efficacy. Additionally, the naphmethonium fragment lowered the maximum effect of pilocarpine, whereas the activity of isopilocarpine was increased. The intensity of both effects was influenced by the subtype selectivity produced by naphmethonium leading, in the case of the pilocarpine hybrid, to less decreased responses or, in the case of the isopilocarpine hybrid, to more increased responses at the M2 and M4 receptors. The results generally lead to the assumption that the allosteric moiety strongly influences the binding poses of the hybrid ligands so that the orthosteric fragments do not interact with the binding site in the same way as the orthosters alone. A second project was based on molecular dynamics simulations of the binding pose of pilocarpine,[73] leading to the hypothesis that the partial agonism of pilocarpine results from an equilibrium between an agonistic and an antagonistic binding pose at the orthosteric binding site of the receptor. The ratio of occupancy of both binding poses determines the observed efficacy of pilocarpine. The orthosteric binding site provides more space for the ethyl substituent in the supposed antagonistic pose than in the agonistic binding pose. This hypothesis was tested by the synthesis and pharmacological evaluation of pilocarpine analogues with alkyl substituents of different sizes at the lactone (16, 31a, c, d) (Figure 44). The analogues with larger alkyl residues are expected to shift the equilibrium towards the antagonistic binding pose, the analogues with smaller residues should have the inverse effect. The synthesis of the pilocarpine analogues was first attempted as a mixture of stereoisomers which were supposed to be separated at the end of the synthetic route. The racemic mixture of the thermodynamically more stable trans-isomers of the target compounds was prepared in a one-pot Michael-addition-alkylation reaction of a dithiane imidazole onto furan-2(5H)-one similarly to the synthesis of pilosinine (Figure 45). The resulting enolate was quenched by an iodoalkane to achieve alkylation of the lactone and subsequent complete deprotection yielded the racemic trans-analogues of pilocarpine.[133] After unsuccessful attempts of chiral resolution, the mixture of trans-isomers was converted to a mixture of all four possible diastereomers in a kinetic epimerisation reaction.[95] A separation of the stereoisomers was not possible in this project so only the racemic molecule 16 (pilosinine, R = H) was obtained from this synthetic route. For the selective synthesis of the cis-isomers following a patent from Reimann,[146] both stereocenters of the target molecules were produced in the last synthetic step by a syn-hydrogenation of the α,β-unsaturated precursor (Figure 46). The racemic pilocarpine analogues, except the butyl derivative (31d), were purified by crystallisation as their nitrate salts. This provided the racemic mixtures with less than 8\% of the trans-isomers as impurity. The racemic pilocarpine (2), itself, was obtained with 15\% trans-impurity and was used as reference compound. Additionally, the possibility of chiral resolution by chromatographic methods was demonstrated in the case of the methyl derivative (31a). The pharmacological testing of the desired enantiomer of 31a is in progress.},
  subject      = {Muskarinrezeptor},
  language  = {en}
}